Related Experiment Video
Updated: May 3, 2026
08:32
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
25.3K
N alpha methyl histamine versus propranolol in migraine prophylaxis
Summary
N alpha methyl histamine administered subcutaneously and oral propranolol similarly reduce migraine symptoms. This suggests N alpha methyl histamine is a novel, effective treatment for migraine prophylaxis.
Area of Science:
- Neurology
- Pharmacology
Background:
- N alpha methyl histamine exhibits selective H3 receptor affinity.
- Potential for N alpha methyl histamine as a novel migraine prophylaxis agent.
Purpose of the Study:
- To compare the efficacy and tolerability of subcutaneous N alpha methyl histamine versus oral propranolol for migraine prophylaxis.
Main Methods:
- A 12-week double-blind controlled trial involving 60 migraine patients.
- Subcutaneous N-alpha methyl histamine (1-3 ug twice weekly) vs. oral propranolol (120 mg/day).
- Evaluated headache intensity, frequency, duration, and analgesic intake.
Main Results:
- 55 patients completed the study.
- Both N alpha methyl histamine and propranolol significantly reduced all measured variables (p<0.01).
Conclusions:
- N alpha methyl histamine and propranolol demonstrate comparable efficacy in migraine prophylaxis.
- Low-dose subcutaneous N-alpha methyl histamine offers a novel therapeutic option.
- Supports H3 receptor agonists as a viable strategy for migraine treatment.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:24Antiasthma Drugs: Methylxanthines
2.0K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K